Jenburkt Pharmaceuticals Limited (JENBURPH) fundamentals
Jenburkt Pharmaceuticals Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as JENBURPH (ISIN INE354A01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Jenburkt Pharmaceuticals Limited does
Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and healthcare products. The Company offers pharmaceutical products for various therapeutic areas, including analgesic and antipyretics, anthelmintics, anti-arthritics, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer products, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets, Topcal-M Tablets, Powergesic, ZIX P Tablet, and others. The Company's manufacturing plant is in Sihor, Gujarat.
Valuation and market data
| Last close | ₹1003.90 |
|---|---|
| Market capitalisation | ₹443 crore |
| Enterprise value | ₹443 crore |
| P/E (TTM) | 12.75 |
| Price to book | 2.25 |
| Price to sales (TTM) | 1.49 |
| Book value per share | ₹446.40 |
| Dividend yield | 206.20% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Mon Aug 17 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹179 crore | ₹47 crore | ₹35 crore | 78.71 |
| Mar 2025 | ₹158 crore | ₹44 crore | ₹32 crore | 72.65 |
| Mar 2024 | ₹147 crore | ₹35 crore | ₹26 crore | 58.86 |
| Mar 2023 | ₹142 crore | ₹33 crore | ₹25 crore | 53.90 |
| Mar 2022 | ₹129 crore | ₹30 crore | ₹22 crore | 48.58 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 46.6% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.1% |
| Retail and others | 53.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.